Building a strong presence as a specialist dermatology company, Oraderm Pharmaceuticals is a joint venture between Arrotex Pharmaceuticals and Douglas Pharmaceuticals.
Arrotex Pharmaceuticals is the largest by volume, and most diverse, pharmaceutical company in Australia, with well established distribution channels for products and services to pharmacies and hospitals.
Founded in New Zealand, Douglas Pharmaceuticals works with innovative partners to research, develop, manufacture, market, and distribute prescription and over-the-counter pharmaceutical, nutraceutical, and other consumer healthcare products. From humble beginnings over 50 years ago, Douglas now has an ever-expanding footprint into local and global markets.
As a specialist dermatology company supporting healthcare practitioners, pharmacists and patients in treating debilitating skin conditions, the joint venture allows Oraderm Pharmaceuticals to facilitate opportunities to bring in innovator products from global sources with extensive expertise in bringing products to market and ensuring they are distributed in the most effective way.
Through this combination, Oraderm Pharmaceuticals has built a strong foundation by offering market leading brands helping patients with debilitating skin conditions. Products in the Oraderm range act on the chronic immunological pathway involvement in these conditions. Oraderm Pharmaceuticals also supports access to medicines not available in Australia, via the Therapeutic Goods Administration (TGA) Authorised Prescriber and TGA Special Access Schemes.
Committed to the future of dermatology, Oraderm continues to build on its portfolio and bring to Australia innovative new medicines and build partnerships with healthcare professionals, working together to meet patient needs with the best possible outcomes.